This Article Full Text Full Text (PDF) All Versions of this Article: 39/2/255    most recent STROKEAHA.107.508291v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Quinn, T. J. Articles by Lees, K. R. Search for Related Content PubMed PubMed Citation Articles by Quinn, T. J. Articles by Lees, K. R. Pubmed/NCBI databases Medline Plus Health Information Stroke Related Collections Neuroprotectors Thrombolysis Angioplasty and Stenting Other Stroke Treatment - Surgical

(Stroke. 2008;39:255.)
© 2008 American Heart Association, Inc.

Advances in Stroke 2007

Advances in Emerging Therapies 2007

From the Department Cardiovascular and Medical Sciences, University of Glasgow, UK.

Correspondence to Dr Terence J. Quinn, Gardiner Institute of Cardiovascular and Medical Sciences, Western Infirmary, Glasgow G11 6NT UK. E-mail Tjq1t@clinmed.gla.ac.uk

Key Words: acute care • acute stroke • clinical trials • hyperglycaemia • interventional neuroradiology • intracranial hemorrhage • neuroprotectant • thrombolysis

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Cynics may consider that review of emergent stroke therapies in 2007 is likely to make for quick reading—it is certainly true that many high profile trials reported unexpected neutral outcomes. However, although these disappointments made for headline medical news, there were still a number of encouraging results of novel acute therapies.

The first "casualty" of the year was neuroprotection. The free radical trapping agent NXY-059 had been consistently shown to reduce infarct size and improve functional outcomes in published reports of animal models. The first phase III study in humans (SAINT) was positive, reporting a statistically significant improvement in global disability (Figure).¹ Unfortunately, the follow up SAINT II trial did not confirm this result (Figure).² This randomized placebo-controlled study of 3306 ischemic stroke patients up to 6 hours from ictus demonstrated no significant improvement in the primary end point of day 90 modified Rankin score (mRS). Subgroup analyses also failed to replicate the previous finding of reduced hemorrhagic transformation rate in patients treated with thrombolytic.

View larger version (34K):   Figure. Functional outcomes in major stroke trials of 2007; for comparison results of both SAINT trials are presented.

Although the result was disappointing, the trial itself was rigorous and it optimized statistical analyses to describe functional outcomes across the treatment groups. A clear message from the SAINT trials is that even large-scale meticulously planned trials are subject to the play of chance, and that initial positive results require verification with a second adequately powered study. These themes have been echoed in . . . [Full Text of this Article]